MALVERN, Pa., Jan. 29, 2010 —DSG‘s eCaseLink™ Electronic Data Capture (EDC) and data management are currently being used by a biotechnology company for two current Phase II and Phase IIa clinical trials for treatments of progressive and chronic kidney disease. The company uses DSG’s eCaseLink™ to automate and manage the data collection process during the clinical trial lifecycle. In addition, DSG combines data management services with eCaseLink™ to seamlessly optimize data collection and analysis.
Read more ...
BusinessWire - DSG's eCaseLink(TM) Electronic Data Capture (EDC) and data management are currently being used by a biotechnology company for two current phase 2 and phase 2a clinical trials for treatments of progressive and chronic kidney disease. The company uses DSG's eCaseLink(TM) to automate and manage the data collection process during the clinical trial lifecycle. In addition, DSG combines data management services with eCaseLink(TM) to seamlessly optimize data collection and analysis.
Read more ...
DSG’s electronic data capture and data management vital for two ongoing clinical trials.
MALVERN, Pa., Jan. 11, 2010 — DSG’s eCaseLink™ Electronic Data Capture (EDC) and data management are currently being used by a biotechnology company for two current phase 2 and phase 2a clinical trials for treatments of progressive and chronic kidney disease.
Read more ...
DSG PARTNERS WITH BIOTECH COMPANY TO BATTLE PROGRESSIVE AND CHRONIC KIDNEY DISEASE
DSG’s electronic data capture and data management vital to two ongoing clinical trials.
MALVERN, Pa., Jan. 11, 2010 — DSG’s eCaseLink™ Electronic Data Capture (EDC) and data management are currently being used by a biotechnology company for two current phase 2 and phase 2a clinical trials for treatments of progressive and chronic kidney disease.
Read more ...
DSG's EDC Used in Current Alzheimer's, Parkinson's and Diabetes Trials
Malvern, Pa., Jan. 18, 2010 - DSG, a provider of electronic data capture (EDC) solutions, has teamed up with a leading-edge pharmaceutical company to speed the early detection of Alzheimer’s, Parkinson’s, and Diabetes.
Read more ...
DSG & PHARMACEUTICAL COMPANY ENGAGE IN GLOBAL EFFORT IN EARLY DETECTION OF MAJOR DISEASES. — EDC technology supports studies on early detection for Alzheimer’s, Parkinson’s and Diabetes —
MALVERN, Pa., Jan. 11, 2010 — DSG, a leader in electronic data capture (EDC) has teamed up with a leading-edge pharmaceutical company to speed the early detection of Alzheimer’s, Parkinson’s, and Diabetes.
Read more ...
DSG & PHARMACEUTICAL COMPANY ENGAGE IN GLOBAL EFFORT IN EARLY DETECTION OF MAJOR DISEASES. — EDC technology supports studies on early detection for Alzheimer’s, Parkinson’s and Diabetes —
MALVERN, Pa., Jan. 11, 2010 — DSG, a leader in electronic data capture (EDC) has teamed up with a leading-edge pharmaceutical company to speed the early detection of Alzheimer’s, Parkinson’s, and Diabetes.
Read more ...
New Risks Require New Solutions
OCTOBER, 2009 A clear and present danger has emerged for the pharmaceutical and medical device industry that threatens its very core. After a wave of criticism about the way federal drug regulators are performing their duty, a Supreme Court majority handed down a decisive endorsement of lawsuits in state courts to address deficiencies at the national level.
Read more ...
100% EDC, A Necessity. From “Is 100% EDC Realistic?” presented by Suzanne Lamerand of DSG, Inc. at the 2009 SCDM Annual Conference, 2009.
The pharmaceutical and device industry faces a hostile litigious and regulatory environment. This current climate can stifle research and, as a result, impede progress that could improve the healthcare of all Americans. The concern is over a new level of scrutiny aimed at pharmaceutical and medical device companies. The good news is that the industry can employ existing technologies to head off potential problems and dramatically reduce risk. That technology is EDC.
Read more ...
50 Years is a Long Time to Wait for a Drug
By Lisa Henderson | Published: October 6, 2009 Lupus, a chronic, severe autoimmune disease that effects 1.5 million Americans, primarily women in their childbearing years, can lead to kidney failure, heart attack, atherosclerosis or death.
Read more ...
DSG in the Spotlight at 2009 SCDM Annual Conference -- DSG's EDC technology presence at 2009 SCDM conference highly anticipated
MALVERN, Pa., Oct 01, 2009 (BUSINESS WIRE) -- DSG, Inc., the leader in EDC and clinical software technology, is already the center of attention leading up to the 2009 SCDM Annual Conference. The excitement is centered around DSG's continuing role as a pioneer in the EDC (electronic data capture) field, with over 500 attendees eager to see the latest developments and the future of EDC from DSG.
Read more ...
DSG in the Spotlight at 2009 SCDM Annual Conference
(01 Oct 2009) -DSG's EDC technology presence at 2009 SCDM conference highly anticipated - MALVERN, Pa.--(Business Wire)-- DSG, Inc., the leader in EDC and clinical software technology, is already the center of attention leading up to the 2009 SCDM Annual Conference. The excitement is centered around DSG`s continuing role as a pioneer in the EDC(electronic data capture) field, with over 500 attendees eager to see the latest developments and the future of EDC from DSG.
Read more ...
Cipher Uses DSG’S EDC In Effort To Give Hope To Severe Acne Sufferers
(01 Oct 2009) DSG Inc., an industry leader in clinical trial data collection and management, today announced that Cipher Pharmaceuticals is using electronic data capture (EDC) software and data management services from DSG. Cipher is using DSG’s eCaseLink for its Phase 3 dermatology study on its new compound for the treatment of severe acne. Cipher’s new treatment offers new hope for patients with severe inflammatory or recalcitrant nodular acne who are unresponsive to conventional therapy.
Read more ...
Cipher Uses DSG`s EDC in Effort to Give Hope to Severe Acne Sufferers
(14 Sep 2009) -Cipher Pharmaceuticals conducts Phase 3 trial study for new severe acne treatment- MALVERN, Pa.-- DSG Inc., an industry leader in clinical trial data collection and management, today announced that Cipher Pharmaceuticals (TSX:DND) is using electronic data capture (EDC) software and data management services from DSG. Cipher is using DSG`s eCaseLink for its Phase 3 dermatology study on its new compound for the treatment of severe acne. Cipher`s new treatment offers new hope for patients with severe inflammatory or recalcitrant nodular acne who are unresponsive to conventional therapy.
Read more ...
Cipher Uses DSG’s EDC in Effort to Give Hope to Severe Acne Sufferers
(14 Sep 2009) DSG Inc., an industry leader in clinical trial data collection and management, today announced that Cipher Pharmaceuticals (TSX:DND) is using electronic data capture (EDC) software and data management services from DSG. Cipher is using DSG’s eCaseLink™ for its Phase 3 dermatology study on its new compound for the treatment of severe acne. Cipher’s new treatment offers new hope for patients with severe inflammatory or recalcitrant nodular acne who are unresponsive to conventional therapy.
Read more ...
DSG’s Successes with Human Genome Sciences
By Lisa Henderson | Published: September 2, 2009 In covering clinical trials, we are seeing more focus on the activities in specific therapeutic areas. Not that they didn’t exist before, but the frequency with which companies are identifying the specific conditions for which they have experience are on an uptick. These experiences can parlay into other contracts in similar conditions, or add to the company’s cadre of experience, as well as the overall impression, the company already exhibits.
Read more ...
DSG Helps Human Genome Achieve Phase III Success
(17 Aug 2009) Human Genome Sciences (HGS; Rockville, MD) credits EDC technology from DSG (Malvern, PA) for helping the company meet the primary endpoint in two Phase III trials of its Lupus drug BENLYSTA.
Read more ...
Human Genome Sciences is using the electronic data capture (EDC)
(17 Aug 2009) Human Genome Sciences is using the electronic data capture (EDC) solution from DSG in four Phase III trials. One recent trial had 400 unique case report forms for each subject. Said Pierre Verroye, executive director of clinical data management at Human Genome Sciences: “DSG solved emerging, unprecedented challenges through innovation and by adding completely new functionality to HGS' system. Sites and clinical research assistants gave us a lot of positive feedback about the eCaseLink system.”
Read more ...
Human Genome Sciences Achieves Lupus Drug Goals With DSG`s EDC
(17 Aug 2009) Human Genome Sciences announced that BENLYSTA met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). These results show that BENLYSTA has the potential to become the first new approved drug in decades giving hope to people living with systemic lupus.
DSG supports HGS on four global Phase 3 studies concurrently, providing data capture and supporting data management through its function rich eCaseLink EDC software. The study included nearly 400 electronic case report forms per subject, which were highly complex in design and had nearly 1,200 edits per screen. DSG provided critical data reporting tools based on study requirements, allowing HGS data management personnel to continually monitor and efficiently insure data quality.
Read more ...
Human Genome Achieves Lupus Drug Goals With DSG’s EDC
(17 Aug 2009) Human Genome Sciences (HGS: NASDAQ: HGSI) announced that BENLYSTA™ met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). These results show that BENLYSTA™ has the potential to become the first new approved drug in decades giving hope to people living with systemic lupus.
Read more ...
DSG Announces Record Growth for First Half of 2009
(June 25, 2009) DSG Inc., the industry leader in electronic data capture (EDC) for clinical trial data collection and management, today announced, from the 45th Annual Meeting of the Drug Information Association, its continued record growth and profitability for the first half of 2009.
Read more ...
DSG Announces Record Growth for First Half of 2009
(22 June 2009) DSG Inc., the industry leader in electronic data capture (EDC) for clinical trial data collection and management, today announced, from the 45th Annual Meeting of the Drug Information Association, its continued record growth and profitability for the first half of 2009.
Read more ...
Re-branding, EDC, and swag … oh my!
(April 29, 2009) -- Speaking of EDC: I chatted briefly with Tony Varano, who founded e-clinical vendor DSG 17 years ago.
Read more ...
DSG, Inc. wins SCDM Data Driven Innovation Award for second year in a row
(Jan. 13, 2009) – DSG’s collaborative work with Human Genome Sciences wins key industry award...
Read more ...